Company Profile
Sera Prognostics Stock Price, News & Catalysts
- Ticker:
- SERA
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
1.95 USD (-0.51%)
Close
Last updated: August 17, 2026
79.9M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, SERA closed down 0.51% at $1.95. No new same-company headline was identified in the current news window.
Company overview
Precision Pregnancy Diagnostics
Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent. Its objective is to support earlier, personalized intervention for mothers and newborns.
PreTRM Test
The PreTRM Test measures maternal blood proteins during weeks 18 through 20 of pregnancy to estimate an individual's risk of spontaneous preterm birth. Physicians can use the result to guide risk-reduction care for higher-risk pregnancies.
Clinical Evidence Base
The test is supported by validation studies and the PRIME randomized controlled trial, which evaluates the clinical and economic effects of PreTRM-guided care. Sera continues to publish subgroup and health-economic analyses from this evidence base.
Payer-Led Adoption Model
Sera works with health plans and state-based programs to implement testing across covered populations. This model combines payer contracting, provider education, reimbursement readiness, and integration into prenatal-care pathways.
Pregnancy Complications Pipeline
Beyond spontaneous preterm birth, Sera is developing diagnostic approaches for other pregnancy complications using its proteomic biomarker platform.
Future catalysts
- Completion of the European CE-mark submission for the PreTRM Test in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sera Prognostics (SERA)?
Sera Prognostics (SERA) most recently closed at 1.95 USD, a -0.51% move versus the previous session.
What is the market cap of Sera Prognostics (SERA)?
Sera Prognostics currently has a market capitalization of 79.9M USD on BioPharmSignal.
What does Sera Prognostics do?
Precision Pregnancy Diagnostics Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent. Its objective is to support earlier, personalized intervention for mothers and newborns. PreTRM Test The PreTRM Test measures maternal blood proteins during weeks 18 through 20 of...
On which exchange is SERA stock listed?
Sera Prognostics (SERA) is associated with NASDAQ, United States, MedTech.
What is Precision?
Precision Pregnancy Diagnostics Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent.
Which conditions is Sera Prognostics targeting with Precision?
Precision Pregnancy Diagnostics Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent. Its objective is to support earlier, personalized intervention for mothers and newborns. PreTRM Test The PreTRM Test measures maternal blood proteins during weeks 18 through 20 of...
How does Sera Prognostics describe recent progress with Precision?
Completion of the European CE-mark submission for the PreTRM Test in the fourth quarter of 2026.
What is Pregnancy?
Precision Pregnancy Diagnostics Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent.